Notably, a certain amount of circulating sPD-L1 acts to suppress the PD-1/PD-L1 pathway, thereby fostering chronic immune responses and inflammation, ultimately accelerating the pathological progression of CHD (31). Here, SPDL1 is linked to coronary artery disorder.